logo
welcome
Wired

Wired

The Uncertain Path Forward for Psychedelic Medicine

Wired
Summary
Nutrition label

75% Informative

MDMA was poised to become an approved treatment for post-traumatic stress disorder.

The FDA last week declined to approve MDMA for treating PTSD based on current evidence.

The journal Psychopharmacology retracted three papers authored by Lykos Therapeutics , the company behind treatment, due to “protocol violations amounting to unethical conduct”.

Spravato can induce disassociation and hallucinogenic effects.

Johnson & Johnson asked the FDA to approve just the drug, rather than the drug alongside psychotherapy.

Biotech company Compass Pathways is testing psilocybin, the active compound in magic mushrooms, in Phase 3 trials for treatment-resistant depression.